Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms

Kamal S. Saini, MD, MBBS; Begoña de las Heras, MD; Ruth Plummer, MD, PhD; Victor Moreno, MD, PhD; Marco Romano, MD; Javier de Castro, MD, PhD; Philippe Aftimos, MD; Judy Fredriksson, BPharm; Gouri Shankar Bhattacharyya, MD, MBBS; Martin Sebastian Olivo, MD; Gaia Schiavon, MD, PhD; Kevin Punie, MD; Jesus Garcia-Foncillas, MD; Ernesto Rogata, GCE A; Richie Pfeiffer, MS; Cecilia Orbegoso, MSc, MD; Kenneth Morrison, BSc, PhD; Giuseppe Curigliano, MD, PhD; Lynda Chin, MD; Monika Lamba Saini, MD, PhD; Øystein Rekdal, PhD; Steven Anderson, PhD; Javier Cortes, MD, PhD; Manuela Leone, MD; Janet Dancey, MD; Chris Twelves, BMedSci, MD; and Ahmad Awada, MD, PhD

[1]  E. Eisenhauer,et al.  Covid-19 Pandemic-An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology? , 2020, JAMA oncology.

[2]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[3]  I. Moreno,et al.  Increased vulnerability of clinical research units during the COVID‐19 crisis and their protection , 2020, Cancer.

[4]  Dawn L. Hershman,et al.  Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials , 2020, JAMA network open.

[5]  G. Doherty,et al.  Rethinking cancer clinical trials for COVID-19 and beyond , 2020, Nature Cancer.

[6]  G. Elwyn,et al.  Implications for Telehealth in a Postpandemic Future: Regulatory and Privacy Issues. , 2020, JAMA.

[7]  Laura A. Levit,et al.  Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. , 2020, JCO oncology practice.

[8]  C. Taniguchi,et al.  Cancer Research after COVID-19: Where Do We Go from Here? , 2020, Cancer Cell.

[9]  S. Mandrekar,et al.  Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical Trials , 2020, Journal of Cancer Education.

[10]  G. Bodoky,et al.  ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy , 2020, ESMO Open.

[11]  G. Curigliano,et al.  Effect of the COVID-19 pandemic on cancer treatment and research , 2020, The Lancet Haematology.

[12]  B. Waissengrin,et al.  Breaking Bad News via Telemedicine: A New Challenge at Times of an Epidemic. , 2020, The oncologist.

[13]  R. Platt,et al.  Evidence from Pragmatic Trials during Routine Care - Slouching toward a Learning Health System. , 2020, The New England journal of medicine.

[14]  E. Small,et al.  Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research? , 2020, Contemporary Clinical Trials.

[15]  R. Ohannessian,et al.  Global Telemedicine Implementation and Integration Within Health Systems to Fight the COVID-19 Pandemic: A Call to Action , 2020, JMIR public health and surveillance.

[16]  G. Melloni,et al.  Artificial intelligence and radiomics enhance the positive predictive value of digital chest tomosynthesis for lung cancer detection within SOS clinical trial , 2020, European Radiology.

[17]  J. Hollander,et al.  Virtually Perfect? Telemedicine for Covid-19. , 2020, The New England journal of medicine.

[18]  M. Mckee,et al.  Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. , 2020, JAMA.

[19]  J. Zibert,et al.  Virtual Clinical Trials: Perspectives in Dermatology , 2020, Dermatology.

[20]  J. Gribben,et al.  Reducing Bureaucracy in Clinical Research: A Call for Action , 2020, HemaSphere.

[21]  M. Sydes,et al.  Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement , 2020, British Journal of Cancer.

[22]  G. Jackson,et al.  Artificial Intelligence Tool for Optimizing Eligibility Screening for Clinical Trials in a Large Community Cancer Center. , 2020, JCO clinical cancer informatics.

[23]  C. Moskaluk,et al.  Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. , 2019, American journal of clinical pathology.

[24]  Marcus Woo,et al.  An AI boost for clinical trials , 2019, Nature.

[25]  Jennifer Elston-Lafata,et al.  Challenges and opportunities using online portals to recruit diverse patients to behavioral trials , 2019, J. Am. Medical Informatics Assoc..

[26]  Jonathan M Marron,et al.  Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Christine Micheel,et al.  Conceptual Framework to Support Clinical Trial Optimization and End-to-End Enrollment Workflow , 2019, JCO clinical cancer informatics.

[28]  M. Knoll,et al.  A Big World Made Small: Using Social Media to Optimize Patient Care. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[29]  Jens Rittscher,et al.  The use of digital pathology and image analysis in clinical trials , 2019, The journal of pathology. Clinical research.

[30]  Razelle Kurzrock,et al.  Cancer research in the United States: A critical review of current status and proposal for alternative models , 2018, Cancer.

[31]  Samuel L Volchenboum,et al.  Use of Wearable, Mobile, and Sensor Technology in Cancer Clinical Trials. , 2018, JCO clinical cancer informatics.

[32]  Ana Maria Lopez,et al.  Telemedicine in Cancer Care. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[33]  Joanna Coast,et al.  Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension , 2018, JAMA.

[34]  Alan S Campbell,et al.  Wearable non-invasive epidermal glucose sensors: A review. , 2018, Talanta.

[35]  Tim Sprosen,et al.  What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK , 2018, Trials.

[36]  Edward S. Kim,et al.  Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Awada,et al.  How to emerge from the conservatism in clinical research methodology? , 2017, Current opinion in oncology.

[38]  R. Pazdur,et al.  Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology Trials. , 2017, The New England journal of medicine.

[39]  Jay Evans,et al.  Barriers to Scale of Digital Health Systems for Cancer Care and Control in Last-Mile Settings , 2017, Journal of global oncology.

[40]  E. Namey,et al.  Evidence-Based Strategies for Shortening Informed Consent Forms in Clinical Research , 2017, Journal of empirical research on human research ethics : JERHRE.

[41]  M. Ratain,et al.  Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Kurzrock,et al.  An appraisal of drug development timelines in the Era of precision oncology , 2016, Oncotarget.

[43]  John P. A. Ioannidis,et al.  Why Most Clinical Research Is Not Useful , 2016, PLoS medicine.

[44]  Leslie Lenert,et al.  Teleconsent: A novel approach to obtain informed consent for research , 2016, Contemporary clinical trials communications.

[45]  Olivier Chételat,et al.  Clinical validation of LTMS-S: A wearable system for vital signs monitoring , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[46]  M. Romano,et al.  Is the digital divide an obstacle to e-health? An analysis of the situation in Europe and in Italy. , 2015, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[47]  H. Kantarjian,et al.  Impact of cancer research bureaucracy on innovation, costs, and patient care. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  G. Pond,et al.  Data collection in cancer clinical trials: Too much of a good thing? , 2013, Clinical trials.

[49]  Søren Overgaard,et al.  Quality of Data Entry Using Single Entry, Double Entry and Automated Forms Processing–An Example Based on a Study of Patient-Reported Outcomes , 2012, PloS one.